J&J Beats Estimates and Raises Full Year Forecast
Johnson and Johnson reported second-quarter sales of $25.31 billion and adjusted earnings of $2.90 per share, exceeding analyst expectations. Strong demand for drugs like Tremfya and Darzalex offset weaker performance in the medical technology unit, leading the company to raise its annual outlook.
X24 PerspectiveRelated Assets:
X24 Perspective